Cargando…
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
Objective: Lymphatic metastasis is one of the leading causes of malignancy dispersion in various types of cancer. However, few anti-lymphangiogenic drugs have been approved for clinical use to date. Therefore, new therapies to block lymphangiogenesis are urgently required. Methods: Immunohistochemis...
Autores principales: | Qin, Tingting, Liu, Zhujun, Wang, Jing, Xia, Junling, Liu, Shaochuan, Jia, Yanan, Liu, Hailin, Li, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476093/ https://www.ncbi.nlm.nih.gov/pubmed/32944404 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0024 |
Ejemplares similares
-
Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022) -
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
por: Liu, Shaochuan, et al.
Publicado: (2020) -
Fucoidan Suppresses Hypoxia-Induced Lymphangiogenesis and Lymphatic Metastasis in Mouse Hepatocarcinoma
por: Teng, Hongming, et al.
Publicado: (2015) -
Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients
por: Qin, Tingting, et al.
Publicado: (2020) -
Fucoidan inhibits lymphangiogenesis by downregulating the expression of VEGFR3 and PROX1 in human lymphatic endothelial cells
por: Yang, Yazong, et al.
Publicado: (2016)